Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban

DE Houghton, AI Casanegra… - American journal of …, 2020 - Wiley Online Library
Randomized controlled trials leading to the approval of apixaban and rivaroxaban for
venous thromboembolism (VTE) did not include patients with upper extremity deep vein
thrombosis (UE‐DVT). We sought to evaluate the safety and effectiveness of rivaroxaban
and apixaban for the treatment of acute UE‐DVT. Consecutive patients with VTE enrolled
into the Mayo Clinic VTE Registry, between March 1, 2013 and December 31, 2019, were
followed prospectively. Clinical, demographic and imaging data were collected at the time of …

[HTML][HTML] Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban

DE Houghton, J Cochuyt, DO Hodge, D Vlazny… - Blood, 2019 - Elsevier
Background: Randomized controlled trials leading to the approval of apixaban and
rivaroxaban for venous thromboembolism (VTE) did not include patients with UE-DVT.
Limited observational data has been published on outcomes in this setting and no direct
comparison to traditional anticoagulation has been performed. Objective: Evaluate the safety
and effectiveness of rivaroxaban and apixaban for the treatment of acute UE-DVT compared
to low-molecular weight (LWMH) and warfarin. Methods: Consecutive patients with VTE …
以上显示的是最相近的搜索结果。 查看全部搜索结果